The prevention of early postmenopausal bone loss by cyclical etidronate therapy: A 2-year, double-blind, placebo-controlled study

American Journal of Medicine

Volumn 103, Issue 2, 1997, Pages 92-99

  Herd, Ruth J M ^a   Balena, Raffaella ^b   Blake, Glen M ^a   Ryan, Paul J ^a   Fogelman, Ignac ^a  

^a GUY S HOSPITAL   (United Kingdom)

^b PROCTER AND GAMBLE COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; ETIDRONIC ACID;

ADULT; AGED; ARTICLE; BACKACHE; BONE DENSITY; BONE MINERAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN CELL; HUMAN TISSUE; LUMBAR SPINE; MAJOR CLINICAL STUDY; MENOPAUSE; ORAL DRUG ADMINISTRATION; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION;

AMBULATORY CARE; BIOLOGICAL MARKERS; BONE DENSITY; DENSITOMETRY, X-RAY; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ETIDRONIC ACID; FEMALE; FEMUR; HUMANS; LUMBAR VERTEBRAE; MIDDLE AGED; POSTMENOPAUSE; TIME FACTORS; TREATMENT OUTCOME;

EID: 0030753790     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(97)00019-3     Document Type: Article

References (33)

1. Fleisch H. The use of bisphosphonates in osteoporosis. Br J Clin Pract. 1994;48:323-326.
2. Geddes AD, D'Souza SM, Ebetino FH, Ibbotson KJ. Bisphosphonates: structural-activity relationships and therapeutic implications. Heersche JNM, Kanis J (eds.) In: Bone and Mineral Research/8. Amsterdam: Elsevier, 1995:265-306.
3. Powell JH, DeMark BR. Clinical pharmacokinetics of diphosphonates. Grattini S (ed) In: Bone resorption, metastasis, and diphosphonates. New York: Raven Press, 1985;41-49.
4. Papapoulos SE. The role of bisphosphonates in the prevention and treatment of osteoporosis. Am J Med. 1993;95:48S-52S.
5. Rodan GA, Balena R. Bisphosphonates in the treatment of metabolic bone diseases. Ann J Med. 1993;25:373-378.
6. Wimalawansa SJ. Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: four-year randomized study. Am J Med. 1995;99:36-42.
7. Eisman JA, Christiansen C, McClung M, et al. Alendronate prevents bone loss at the spine and hip in recently postmenopausal women. J Bone Miner Res. 1995;10(suppl):S176.
8. Reginster JY, Lecart MP, Deroisy R, et al. Prevention of postmenopausal bone loss by tiludronate. Lancet. 1989;ii:1469-1471.
9. Cummings SR, Black DM, Nevitt MC, et al. Bone density at various sites for prediction of hip fractures. Lancet 1993;341:72-75.
10. Hui SL, Slemenda CW, Johnston CC. Baseline measurement of bone mass predicts fracture in white women. Ann Intern J Med. 1989;111:355-361.
11. Melton LJ, Atkinson EJ, O'Fallon WM, et al. Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res. 1993;8:1227-1233.
12. Hui SL, Slemenda CW, Johnston CC. Age and bone mass as predictors of fracture in prospective study. J Clin Invest. 1988;81:1804-1809.
13. Compston JE, Cooper C, Kanis JA. Bone densitometry in clinical practise. Br J Med J. 1995;310:1507-1510.
14. Cooper C, Fogelman I, Melton LJ. Bisphosphonates and vertebral fracture: an epidemiological perspective. Osteoporosis Int. 1991;2:1-4.
15. Storm T, Thamsborg G, Steiniche T, et al. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. NEJM. 1990;322:1265-1271.
16. Ryan PJ, Blake GM, Fogelman I. Postmenopausal screening for osteopenia. Br J Rheumatol. 1992;31:823-828.
17. Reeve J. Future prospects for hormone replacement therapy. Br J Med Bull. 1992;48:458-468.
18. Sagraves R. Estrogen therapy for postmenopausal symptoms and prevention of osteoporosis. J Clin Pharm. 1995;35:2-10.
19. Henderson VW, Paganini-Hill A, Emanuel CK, et al. Estrogen replacement therapy in older women: comparisons between Alzheimer's disease cases and nondemented control subjects. Arch Neurol. 1994;51:896-900.
20. Colditz GA, Egan KM, Stampfer MJ. Hormone replacement therapy and risk of breast cancer: results from epidemiologic studies. Am J Obstet Gynecol. 1993;168:1473-1480.
21. Bilezikian JP. Major issues regarding estrogen replacement therapy in postmenopausal women. J Women's Health. 1994;3:273-282.
22. Davidson NE. Hormone-replacement therapy - breast versus heart versus bone. NEJM. 1995;332:1638-1639.
23. Lindsay R, Bush TL, Grady D, et al. Therapeutic controversy, estrogen replacement in menopause. J Clin Endo & Met. 1996;81:3829-3838.
24. Sismond P, Biglia N, Giai M, Campagnoli C. Hormone replacement therapy and breast cancer. Eur Menopause J. 1996;3:227-231.
25. Cummings SR, Black DM, Vogt TM. Changes in BMD substantially underestimate the anti-fracture effects of alendronate and other antiresorptive drugs. J Bone Miner Res. 1996;11:Suppl 1:S102.
26. Miller PD, Neal BJ, McIntyre DO, et al. Effect of cyclical therapy with phosphorus and etidronate on axial bone mineral density in postmenopausal osteoporotic women. Osteoporosis Int. 1991;1:171-176.
27. Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. Study of osteoporotic fractures research group. NEJM. 1995;767-773.
28. Harris S, Dawson-Hughes B. Rates of change in bone mineral density of the spine, heel, femoral neck, and radius in healthy postmenopausal women. Bone Miner. 1992;17:87-95.
29. Pouilles JM, Tremollieres F, Ribot C. Effect of menopause on femoral and vertebral bone loss. J Bone Min Res. 1995;10:1531-1536.
30. Sacco-Gibson N, Lowry C, Smith J, et al. Bone marker changes in etidronate or estrogen treated postmenopausal women are similar. J Bone Miner Res. 1995;10(suppl):S351.
31. Lufkin EG, Argueta R, Whitaker MD, et al. Pamidronate: an unrecognized problem in gastrointestinal tolerability. Osteoporosis Int. 1994;4:320-322.
32. De Groen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. NEJM. 1996;335:1016-1021.
33. Castell DO. "Pill Esophagitis" - the case of alendronate. NEJM. 1996;335:1058-1059.